SCHOLAR ROCK HOLDING CORP (SRRK)
NASDAQ • Healthcare
$54.72
+$2.67 (+5.1%)
Market open
Last close at August 18, 2026 at 20:00 UTC
Fundamentals Charts
About SCHOLAR ROCK HOLDING CORP
Name
SCHOLAR ROCK HOLDING CORP
CEO
David L. Hallal
Website
Industry
Healthcare
Year Founded
2012
Employees
289
Scholar Rock Holding Corporation develops targeted therapies that modulate protein growth factor signaling as a NASDAQ-listed biotechnology company. The company focuses on precision inhibitors of transforming growth factor beta, or TGF-beta, activation and advances programs in neuromuscular disease, cancer, and fibrotic disease research.
Fundamentals & Financials
Revenue (TTM)
$0
Net Income (TTM)
-$408.5M
EPS (TTM)
-$3.31
ROA (TTM)
-78.04%
Current Ratio
7.02
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Stay Ahead of the Market
Get premium market insights delivered directly to your inbox.
Quote Summary
Previous CloseDay Range$54.72$51.91 - $54.78
52 Week RangeAvg. Volume$27.07 - $58.491M
Market Cap$6.5B
Peers & Related Assets
XENEXENON PHARMACEUTICALS INC
$63.18+1.3%
ADPTADAPTIVE BIOTECHNOLOGIES CORP
$24.56-0.8%
IDYAIDEAYA BIOSCIENCES INC
$37.93+3.8%
IRONDISC MEDICINE INC
$80.2+0.2%
BEAMBEAM THERAPEUTICS INC
$26.57-2.0%
MLYSMINERALYS THERAPEUTICS INC
$26.61+2.1%
KNSAKiniksa Pharmaceuticals International, plc
CDTXCidara Therapeutics, Inc.
LEGNLegend Biotech Corporation
ZLABZai Lab Limited